PRESS RELEASE
Calgary, Canada and Singapore — 2026-08-21
Qualisure Diagnostics Inc. and Invitrocue today announced a strategic collaboration to introduce Thyroid GuidePx®, Qualisure’s RNA-based diagnostic for papillary thyroid cancer, to Singapore and the broader ASEAN region.
The collaboration combines Qualisure’s expertise in RNA-based diagnostics with Invitrocue’s established capabilities in precision medicine, advanced laboratory services, and oncology across Asia. Together, the organizations aim to expand access to advanced molecular diagnostics while laying the foundation for future innovations in RNA-based cancer testing.
Thyroid GuidePx® is an RNA-based diagnostic that analyzes tumour gene expression to provide clinically actionable information about the biological behaviour of papillary thyroid cancer. The test is designed to support physicians with treatment planning by improving risk assessment and helping inform decisions regarding surgical management, radioactive iodine therapy, and long-term follow-up.
As precision oncology increasingly relies on molecular information to guide patient care, both organizations share a vision of making advanced diagnostics more accessible through high-quality local laboratory testing supported by sophisticated bioinformatics and clinical interpretation.
“This collaboration represents an important milestone in our mission to make advanced molecular diagnostics available to more patients around the world,” said Dr. Oliver Bathe, Founder and Chief Executive Officer of Qualisure Diagnostics. “Invitrocue has built an exceptional reputation for innovation and clinical excellence throughout Asia, making them an outstanding partner as we expand access to RNA-based precision oncology.”
“For us, precision oncology is not simply about generating more molecular data—it is about translating that data into clear, timely and clinically actionable decisions for each patient,” said Dr. Steven Fang, Chief Executive Officer of Invitrocue. “By combining Qualisure’s RNA-based technology and computational expertise with Invitrocue’s clinical laboratory capabilities and regional network, we aim to make Thyroid GuidePx® accessible across Singapore and Asia while building a broader platform for RNA diagnostics that can support more personalised cancer care throughout Asia.”
The partnership will initially focus on introducing Thyroid GuidePx® within Singapore before expanding throughout the ASEAN region. Beyond thyroid cancer, the companies intend to
explore opportunities to jointly develop and deploy additional RNA-based diagnostics across a broad range of oncology applications.
By combining complementary expertise in molecular biology, computational medicine, clinical laboratory operations, and regional healthcare implementation, Qualisure Diagnostics and Invitrocue aim to accelerate the adoption of next-generation precision oncology technologies that improve clinical decision-making and patient outcomes.
About Qualisure Diagnostics
Qualisure Diagnostics is a Canadian precision oncology company developing RNA-based diagnostics that transform transcriptomic data into clinically actionable insights. Through its Molecular deCodeR™ platform, the company enables decentralized molecular testing with centralized computational intelligence, making advanced precision oncology accessible to laboratories and clinicians worldwide.
About Invitrocue
Invitrocue is a precision medicine company delivering advanced laboratory services, translational oncology solutions, and digital health technologies across Asia. By integrating innovative laboratory capabilities with cutting-edge computational approaches, Invitrocue supports clinicians, researchers, and biopharmaceutical partners in advancing personalized cancer care.